South Korea's Strict Drug Ban on Mounjaro, Wegovy Sparks Traveler Outcry

South Korea has intensified its crackdown on travelers bringing prescribed Mounjaro and Wegovy into the country, leading to widespread customs seizures and frustration among patients. These popular weight-loss and diabetes medications are being stopped at the border, even with valid overseas prescription, as authorities classify them as 'potentially harmful' and subject to strict import rules. The government's move, reaffirmed in September, aims to combat a surge in illegal imports and misuse, but it leaves legitimate patients facing confiscated medication and much higher costs for local alternatives. The number of illegal imports of these drugs has surged dramatically, with customs officials reporting a more than threefold increase in seizures in the first half of 2026 compared to all of 2025. Many individuals, including tourists and international students, are caught off guard, as a genuine Mounjaro pen, even with a doctor's note from abroad, cannot simply clear customs without a special 'exemption recommendation certificate'. This strict enforcement comes amid a booming demand for GLP-1 agonists, driven by lower prices in neighboring countries like Japan and a growing interest among younger Koreans for cosmetic weight loss, rather than medical need. Looking ahead, the situation is set to get even more complex. While Mounjaro and Wegovy are approved for local use in South Korea, their high cost without broad National Health Insurance coverage pushes patients to seek cheaper overseas options, creating a cycle of illegal imports. However, a new homegrown GLP-1 obesity drug, EPPE, from Hanmi Pharmaceutical, received approval in October 2026 and is expected to launch soon, potentially offering a more affordable local alternative. Meanwhile, authorities continue to explore designating GLP-1 treatments as 'medications with abuse concerns,' indicating an ongoing push for tighter regulation to balance patient access with public safety.